Behavioral Side Effects of Lamotrigine, Brivaracetam, and Sodium Valproate in Children
Sodium valproate causes the most significant behavioral problems in children, including attention problems, hyperactivity, and externalizing behaviors, and should be avoided when alternatives exist. Lamotrigine causes primarily tics and insomnia, while brivaracetam is associated with irritability and behavioral changes.
Sodium Valproate (Valproic Acid)
Valproate consistently demonstrates the worst behavioral profile among these three medications in pediatric populations. The evidence is particularly strong:
In children with childhood absence epilepsy, valproate produced significantly higher attention problems (score 57.8 vs 54.6 for ethosuximide), total behavioral problems (51.7 vs 46.5), externalizing problems (51.4 vs 45.8), and attention-deficit/hyperactivity problems (55.8 vs 53.0) at 16-20 weeks compared to other antiepileptic drugs 1
These attention problems persisted at 12 months (score 57.9 vs 54.5), indicating this is not merely a transient effect 1
In a large study of 380 children with new-onset epilepsy, valproic acid demonstrated significantly greater behavioral side effects compared to all other antiepileptic drugs except levetiracetam 2
The FDA label explicitly lists emotional lability among the most common adverse reactions (>5%) 3
Critical Clinical Consideration
Children with baseline hyperactivity or impulsivity are at substantially higher risk for behavioral side effects with valproate. Baseline hyperactivity significantly predicted worse behavioral outcomes one month after starting any antiepileptic drug, but this effect was most pronounced with valproate 2. Screen for pre-existing attention problems before initiating valproate.
Lamotrigine
Lamotrigine has a more favorable behavioral profile but specific side effects occur:
Tics and insomnia are the primary nonserious behavioral adverse events, with tics occurring predominantly in children 4
Unusual but documented side effects include eye movement abnormalities, involuntary movements, and behavioral changes that resolve upon discontinuation 5
Importantly, lamotrigine has been associated with beneficial effects on cognition and behavior in some studies 6, distinguishing it from valproate
In prenatal exposure studies, lamotrigine-exposed children showed more attention deficit problems compared to levetiracetam-exposed children, but less anxious behavior 7
Rash Risk Amplification
The risk of serious rash (including Stevens-Johnson syndrome) is 3-fold higher in children (approximately 1%) than adults (0.3%) and is further increased by concomitant valproate use and rapid dose escalation 4, 6. Use slow titration protocols, especially when combined with valproate.
Brivaracetam
Brivaracetam has limited pediatric-specific data but available evidence indicates:
Irritability and behavioral changes are the primary behavioral side effects, though no serious behavioral adverse events are listed 4
In adult studies with various concomitant medications, brivaracetam was well-tolerated with drug-related adverse events ranging from 35.2-48.3% across different combinations 8
Brivaracetam is associated with decreased appetite in children, which may indirectly affect behavior 9
Age-Related Vulnerability
Younger children (ages 2-11 years) experience significantly greater behavioral side effects from antiepileptic drugs compared to adolescents (ages 12-18 years), regardless of which medication is used 2. Mean behavioral side effect scores were 25.08 in children versus 12.36 in adolescents. This developmental vulnerability should inform medication selection, with particular caution regarding valproate in younger age groups.
Clinical Decision Algorithm
- Screen for baseline hyperactivity/impulsivity before initiating any of these medications
- Avoid valproate in children when alternatives exist, particularly in:
- Children with pre-existing attention problems
- Younger children (under 12 years)
- Girls of any age (due to teratogenicity concerns beyond behavioral effects)
- Choose lamotrigine when behavioral tolerability is a priority, using slow titration (especially with concomitant valproate)
- Consider brivaracetam as an alternative with a more neutral behavioral profile, though pediatric data are limited
- Monitor closely at 1 month after initiation, as behavioral side effects typically manifest early 2
Common Pitfall
Clinicians often fail to obtain baseline behavioral assessments before starting antiepileptic drugs. Without baseline data, it becomes impossible to distinguish drug-induced behavioral changes from pre-existing problems or disease progression. Use standardized tools like the Child Behavior Checklist before initiating therapy 2, 1.